Forte Biosciences, INC. (FBRX) — SEC Filings

Overview

Forte Biosciences, INC. (FBRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 1, 2026: Forte Biosciences, Inc. filed an 8-K on April 1, 2026, reporting its financial results and condition for the period ending March 31, 2026. The filing includes financial statements and exhibits, with specific details on operations and financial condition.

Sentiment Summary

Across 41 filings, the sentiment breakdown is: 38 neutral, 3 mixed. The dominant filing sentiment for Forte Biosciences, INC. is neutral.

Filing Type Overview

Forte Biosciences, INC. (FBRX) has filed 19 8-K, 6 10-Q, 3 DEF 14A, 2 10-K, 4 SC 13G/A, 4 SC 13D/A, 1 10-K/A, 1 8-K/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (41)

• 8-K Filing — 8-K · Apr 9, 2026
• Forte Biosciences Files 8-K for Q1 2026 Results — 8-K · Apr 1, 2026 Risk: low
  Forte Biosciences, Inc. filed an 8-K on April 1, 2026, reporting its financial results and condition for the period ending March 31, 2026. The filing includes f
• Forte Biosciences' Losses Widen Amid R&D Surge, Cash Position Strengthens — 10-Q · Nov 14, 2025 Risk: high
  Forte Biosciences, Inc. (FBRX) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $44.587 million, up from $28.3
• Forte Biosciences Files 8-K on Operations and Financials — 8-K · Aug 14, 2025 Risk: low
  On August 14, 2025, Forte Biosciences, Inc. filed an 8-K report detailing its results of operations and financial condition. The filing also included informatio
• Forte Biosciences' Cash Soars Amid Rising R&D, Widening Losses — 10-Q · Aug 14, 2025 Risk: high
  Forte Biosciences, Inc. (FBRX) reported a net loss of $26.9 million for the six months ended June 30, 2025, an increase from a net loss of $19.9 million for the
• Forte Biosciences Files 8-K for Material Agreement — 8-K · Jun 25, 2025 Risk: medium
  On June 24, 2025, Forte Biosciences, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial sta
• 8-K Filing — 8-K · Jun 23, 2025
• Forte Biosciences Files 8-K on Security Holder Vote Matters — 8-K · May 30, 2025 Risk: low
  On May 29, 2025, Forte Biosciences, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, formerly known as Toc
• Forte Biosciences Files 8-K on Financials — 8-K · May 15, 2025 Risk: low
  Forte Biosciences, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing also includes financial stateme
• Forte Biosciences Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
  Forte Biosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Tocagen Inc., is involved in pharmaceutical preparat
• Forte Biosciences Files 2025 DEF 14A — DEF 14A · Apr 30, 2025 Risk: low
  Forte Biosciences, Inc. filed a DEF 14A on April 30, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other cor
• Forte Biosciences Relocates Principal Executive Offices — 8-K · Apr 18, 2025 Risk: low
  On April 18, 2025, Forte Biosciences, Inc. filed an 8-K report. The filing indicates that the company's principal executive offices are now located at 3060 Pega
• Forte Biosciences Files 8-K on Financials — 8-K · Apr 4, 2025 Risk: low
  Forte Biosciences, Inc. filed an 8-K on April 4, 2025, reporting on its results of operations and financial condition as of March 31, 2025. The filing includes
• Forte Biosciences Files 2024 Annual Report — 10-K · Mar 28, 2025 Risk: medium
  Forte Biosciences, Inc. filed its 2024 annual report on March 28, 2025, detailing its financial performance and business operations. The company, formerly known
• Forte Biosciences Files 8-K: Director Changes & Officer Compensation — 8-K · Jan 24, 2025 Risk: medium
  On January 24, 2025, Forte Biosciences, Inc. filed an 8-K report detailing several key events. The company announced the departure of a director, the election o
• Forte Biosciences Files Definitive Proxy Statement — DEF 14A · Dec 31, 2024 Risk: low
  Forte Biosciences, Inc. filed its definitive proxy statement on December 31, 2024, for the fiscal year ending December 31, 2024. The filing, designated as DEF 1
• SC 13G/A Filing — SC 13G/A · Dec 6, 2024
• Forte Biosciences Files 8-K Report — 8-K · Dec 3, 2024 Risk: low
  On December 3, 2024, Forte Biosciences, Inc. filed an 8-K report detailing other events and financial statements. The company, formerly known as Tocagen Inc., i
• Forte Biosciences Files 8-K: Material Agreement & Equity Sales — 8-K · Nov 20, 2024 Risk: medium
  On November 19, 2024, Forte Biosciences, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Forte Biosciences Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: medium
  Forte Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the third quarter of
• Forte Biosciences Names New Director and CMO — 8-K · Sep 20, 2024 Risk: medium
  Forte Biosciences, Inc. announced on September 17, 2024, the departure of Director Dr. David S. Scholl and the election of Dr. Jonathan S. Roth as a new directo
• Forte Biosciences Files 8-K on Security Holder Rights — 8-K · Aug 30, 2024 Risk: medium
  On August 27, 2024, Forte Biosciences, Inc. filed an 8-K report detailing material modifications to the rights of security holders and other events. The filing
• Forte Biosciences Appoints New Officers, Director Departs — 8-K · Aug 22, 2024 Risk: medium
  On August 20, 2024, Forte Biosciences, Inc. filed an 8-K report detailing several key events. The company announced the departure of director Dr. Jonathan S. Ro
• Forte Biosciences Files 8-K — 8-K · Aug 14, 2024 Risk: low
  Forte Biosciences, Inc. filed an 8-K on August 14, 2024, reporting on its results of operations, other events, and financial statements. The filing indicates th
• Forte Biosciences Q2 2024 Update — 10-Q · Aug 14, 2024 Risk: medium
  Forte Biosciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported research and development expenses for the second quarter of 202
• Forte Biosciences Files Definitive Proxy Statement — DEF 14A · Jul 30, 2024 Risk: low
  Forte Biosciences, Inc. filed its definitive proxy statement (DEF 14A) on July 30, 2024, for its annual meeting on August 20, 2024. The filing concerns the soli
• Camac Fund Ups Stake in Forte Biosciences — SC 13D/A · Jun 17, 2024 Risk: medium
  Camac Fund, LP, through its filing on June 17, 2024, has amended its Schedule 13D regarding Forte Biosciences, Inc. The filing indicates a change in beneficial
• Forte Biosciences Files 8-K for Material Agreement — 8-K · Jun 14, 2024 Risk: medium
  On June 11, 2024, Forte Biosciences, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The company
• Forte Biosciences Files 8-K Report — 8-K · May 13, 2024 Risk: low
  On May 13, 2024, Forte Biosciences, Inc. filed an 8-K report detailing significant corporate events. The filing includes information on the company's results of
• Forte Biosciences, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: low
  Forte Biosciences, Inc. (FBRX) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Forte Biosciences, Inc. filed a 10-Q report for the period ending M
• Forte Biosciences, Inc. Files 10-K/A Amendment — 10-K/A · Apr 29, 2024 Risk: low
  Forte Biosciences, Inc. (FBRX) filed a Amended Annual Report (10-K/A) with the SEC on April 29, 2024. Forte Biosciences, Inc. filed an amended 10-K report for t
• Forte Biosciences Files 8-K — 8-K · Mar 18, 2024 Risk: low
  Forte Biosciences, Inc. filed an 8-K on March 18, 2024, reporting on results of operations, other events, and financial statements. The company, formerly known
• Forte Biosciences, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 18, 2024 Risk: low
  Forte Biosciences, Inc. (FBRX) filed a Annual Report (10-K) with the SEC on March 18, 2024. Forte Biosciences, Inc. filed its annual report on Form 10-K for the
• Forte Biosciences Amends 8-K Filing on Security Holder Vote — 8-K/A · Feb 16, 2024 Risk: low
  Forte Biosciences, Inc. filed an 8-K/A Amendment No. 2 on February 16, 2024, pertaining to an event reported on September 19, 2023. The filing updates informati
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G Filing — SC 13G · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• BML Investment Partners Amends Forte Bio Stake (Amendment 5) — SC 13D/A · Jan 11, 2024
  BML Investment Partners, L.P. filed an amended Schedule 13D/A on January 10, 2024, indicating a change in their beneficial ownership of Forte Biosciences, Inc.
• Funicular Funds Amends Forte Bio Stake, Ma-Weaver Leads — SC 13D/A · Jan 9, 2024
  Funicular Funds, LP, led by Jacob Ma-Weaver, has filed Amendment No. 5 to its Schedule 13D for Forte Biosciences, Inc. This amendment, triggered by an event on
• Camac Fund Amends Forte Bio 13D, Adds ATG Capital Contact — SC 13D/A · Jan 5, 2024
  Camac Fund, LP, a significant shareholder in Forte Biosciences, Inc., has filed an Amendment No. 1 to its Schedule 13D, indicating a change in its beneficial ow

Risk Profile

Risk Assessment: Of FBRX's 31 recent filings, 2 were flagged as high-risk, 12 as medium-risk, and 17 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Forte Biosciences, INC.'s most recent 10-Q filing (Nov 14, 2025):

• Revenue: $0
• Net Income: -$44.587M
• EPS: -$3.26
• Debt-to-Equity: 0.02
• Cash Position: $93.414M
• Operating Margin: N/A
• Total Assets: $97.089M
• Total Debt: $1.299M

Key Executives

• Dallas, Texas
• Dr. David S. Scholl
• Dr. Jonathan S. Roth
• Dr. Paul J. Hastings
• Dr. David M. R. Smith
• Eric Shahinian
• Gabriel Gliksberg

Industry Context

Forte Biosciences operates in the highly competitive biotechnology sector, focusing on developing novel therapeutics for immune-mediated diseases. The company's primary asset, FB102, targets indications like celiac disease, non-segmental vitiligo, and alopecia areata, areas with significant unmet medical needs but also existing and emerging competition. Success hinges on demonstrating clinical efficacy and safety in a landscape where regulatory hurdles are high and patient populations can be challenging to reach.

Top Tags

corporate-governance (7) · 8-K (5) · 8-k (4) · financials (4) · financial-reporting (4) · 10-Q (4) · operations (3) · material-agreement (3) · corporate-filing (3) · proxy-statement (3)

Key Numbers

• Cash and cash equivalents: $93.414M — Increased from $22.244M at December 31, 2024, due to public offering.
• Net loss for nine months ended Sept 30, 2025: $44.587M — Increased from $28.323M in the prior year period.
• Research and development expenses for nine months ended Sept 30, 2025: $36.061M — Increased from $15.634M in the prior year period.
• Accumulated deficit as of September 30, 2025: $198.585M — Reflects cumulative losses since inception.
• Net cash used in operating activities for nine months ended Sept 30, 2025: $34.416M — Increased from $20.736M in the prior year period.
• Proceeds from issuance of common stock and pre-funded warrants: $75.000M — Key financing activity for the nine months ended September 30, 2025.
• Shares of common stock outstanding: 12,526,935 — As of November 7, 2025.
• Reverse stock split ratio: 1-for-25 — Effected on August 27, 2024.
• Net loss for six months ended June 30, 2025: $26.9M — Increased from $19.9M for the same period in 2024
• Research and development expenses for six months ended June 30, 2025: $21.0M — Increased from $9.9M in the prior year, reflecting clinical trial activity
• Accumulated deficit as of June 30, 2025: $180.9M — Indicates significant historical losses
• Net cash used in operating activities for six months ended June 30, 2025: $20.4M — Represents the company's cash burn rate from operations
• SEC File Number: 001-38052 — Identifies the company's filing history with the SEC.
• IRS Employer Identification No.: 26-1243872 — Company's tax identification number
• Reporting Period End Date: 20250331 — Indicates the end of the fiscal quarter for which financial information is reported.

Frequently Asked Questions